Rhodiola And Depression Clinical Research

Last updated: October 4, 2026 - Reviewed by Verdant Wellness Editorial Team

Table of Contents

• What Is Rhodiola Rosea and Why Are Researchers Studying It for Depression?
• The Landmark 12-Week Rhodiola Clinical Depression Trial
• Rhodiola vs Antidepressant: How Does It Compare to Sertraline?
• The 89-Person Study: Rhodiola for Mild Depression
• What the 2022 Review Tells Us About Rhodiola Depression Evidence
• Symptom-Level Benefits: Sleep, Mood, and Emotional Stability
• Dose and Duration: What the Research Suggests
• Emerging Research: What 2026 Studies Are Saying
• Safety, Side Effects, and Drug Interactions
• Frequently Asked Questions
• Bottom Line: Is Rhodiola Ready for Clinical Use in Depression?

Introduction

If you have been searching for natural approaches to depression, you have almost certainly come across rhodiola and depression clinical research. The interest is legitimate. Unlike many herbal supplements that rest on folklore alone, Rhodiola rosea has now been put through randomized controlled trials, head-to-head comparisons with prescription antidepressants, and systematic reviews published in peer-reviewed journals. The results are genuinely interesting — and genuinely nuanced.

This post synthesizes the best available clinical evidence, drawing directly from published trial records, a 2022 PMC systematic review, and a 2026 Frontiers review. By the end, you will understand what the science actually says, where the gaps remain, and how to think about Rhodiola if you or someone you care about is dealing with depression.

Important disclaimer: This article is for informational purposes only. It is not medical advice. If you are experiencing depression, please consult a qualified healthcare professional before starting, stopping, or changing any treatment.

★★★★★ 4.8 · 1,247 reviews

Feel Calm By Bedtime. Focused By Morning.

Adaptogen-based formula. Third-party tested. Made in an FDA-registered facility. Backed by a 60-day money-back guarantee.

Shop Cortisol Drops →

✓ 60-day guarantee ✓ Free shipping $40+ ✓ Ships in 24hrs

What Is Rhodiola Rosea and Why Are Researchers Studying It for Depression?

Rhodiola rosea is a flowering plant native to cold, mountainous regions of Europe and Asia, particularly Siberia, Scandinavia, and the Tibetan Plateau. It belongs to a category of plants called adaptogens — substances traditionally believed to help the body resist physical and psychological stress.

The plant's roots contain a complex mixture of active compounds, the most studied of which are rosavins and salidroside. These compounds appear to influence several neurobiological pathways relevant to mood and mental health, including:

• Monoamine neurotransmitter systems — affecting serotonin, dopamine, and norepinephrine signaling
• HPA axis regulation — modulating the stress hormone cortisol
• Neuroprotective mechanisms — reducing oxidative stress in neuronal tissue
• Anti-inflammatory pathways — relevant because neuroinflammation is increasingly linked to depressive disorders

Because conventional antidepressants like SSRIs can carry significant side effects — including sexual dysfunction, weight gain, insomnia, and emotional blunting — there has been growing clinical interest in whether botanicals like Rhodiola might offer a complementary or alternative approach, particularly for rhodiola mild depression presentations that may not warrant immediate prescription intervention.

The rhodiola and mood connection has been studied in both healthy volunteers under stress conditions and in patients meeting clinical criteria for major depressive disorder (MDD). The latter category is where the most clinically meaningful evidence lies, and it is the focus of this article.

The Landmark 12-Week Rhodiola Clinical Depression Trial

The most significant single study in this area is a 12-week randomized, double-blind, placebo-controlled trial of Rhodiola rosea in adults with mild-to-moderate major depressive disorder. This rhodiola clinical depression trial has been described in the PMC trial record and represents the most methodologically rigorous evaluation of Rhodiola for clinical depression conducted to date.

Study Design

The trial enrolled 57 patients diagnosed with mild-to-moderate MDD. Participants were randomized into three groups:

1. Rhodiola rosea extract
2. Sertraline (a widely prescribed SSRI antidepressant, sold as Zoloft)
3. Placebo

The study ran for 12 weeks and evaluated three primary outcomes:

• Efficacy — measured by validated depression rating scales
• Maximum tolerable dose — to assess the upper limits of safe use
• Safety — tracking adverse events across all three groups

This three-arm design is particularly valuable because it allowed researchers to compare Rhodiola not only against placebo (the standard benchmark) but also against an established, evidence-based treatment. Very few herbal supplement trials take this step.

What the Trial Found

The results were meaningful but measured. Depression improved in both the Rhodiola and sertraline groups compared to placebo. Importantly, the rhodiola antidepressant effect was real and statistically detectable — this was not a null result. However, the magnitude of benefit differed between the two active treatments, a finding we will explore in more detail in the next section.

This study, published in 2014 and accessible through PMC [3], laid the groundwork for subsequent reviews and represents the most direct answer to the question: does Rhodiola rosea help with clinically diagnosed depression? The answer, based on this trial, is yes — with important caveats about effect size and comparison to standard care.

Rhodiola vs Antidepressant: How Does It Compare to Sertraline?

The rhodiola vs antidepressant comparison is where the clinical picture becomes both encouraging and sobering.

Efficacy Comparison

In the 12-week trial of 57 patients, sertraline was more effective than Rhodiola in reducing depression scores relative to placebo. In the 2022 systematic review synthesizing data from this trial [1], researchers calculated odds ratios for global improvement by week 12:

• Rhodiola rosea: 1.4 times the odds of improvement versus placebo
• Sertraline: 1.9 times the odds of improvement versus placebo

Both numbers represent genuine benefit over placebo. But the gap between them is clinically meaningful. Sertraline's advantage over Rhodiola was approximately 0.5 odds ratio units — enough that no clinician should recommend Rhodiola as a direct replacement for a first-line antidepressant in moderate-to-severe MDD.

Tolerability Comparison

Here is where the story becomes more nuanced. While sertraline was more effective, Rhodiola showed significantly fewer adverse effects. This tolerability advantage is not trivial. Antidepressant side effects are one of the primary reasons patients discontinue treatment — and treatment discontinuation is one of the most significant barriers to recovery from depression.

Common side effects with SSRIs like sertraline include:

• Nausea and gastrointestinal distress
• Sexual dysfunction
• Insomnia or sedation
• Weight changes
• Emotional blunting

Rhodiola's cleaner tolerability profile, combined with its statistically significant (if smaller) benefit over placebo, has led some researchers to frame it as a potentially valuable option for:

• Patients with mild depression who want to avoid prescription medications
• Patients who have experienced intolerable side effects from SSRIs
• Patients who prefer an integrative approach under medical supervision
• As an adjunctive strategy alongside other treatments (with appropriate medical oversight)

This nuanced positioning — not "better than antidepressants" but "meaningfully better than placebo with fewer side effects" — is the honest clinical picture that emerges from the rhodiola antidepressant research.

★★★★★ 4.8 · 1,247 reviews

The Adaptogens Your Nervous System Has Been Missing.

Ashwagandha, rhodiola, and phosphatidylserine — clinically-studied ingredients that support healthy cortisol rhythms.

Shop Cortisol Drops →

✓ 60-day guarantee ✓ Free shipping $40+ ✓ Ships in 24hrs

The 89-Person Study: Rhodiola for Mild Depression

Separate from the three-arm trial, a smaller but independently conducted study examined Rhodiola specifically in the context of rhodiola mild depression.

In this study, 89 people took Rhodiola rosea for 42 days. The results showed benefit in mild-to-moderate depression, providing an additional data point supporting Rhodiola's potential in this population segment [4].

Why This Study Matters

While 89 participants over 42 days is not a large-scale trial by pharmaceutical standards, it matters for several reasons:

1. Independent replication: The benefit seen in the larger three-arm trial was replicated in a separate study population and study design, strengthening confidence that the effect is real rather than a statistical artifact.

2. Shorter duration signal: Benefit was detected at 42 days — approximately six weeks. This is comparable to the typical timeline for noticing benefit from conventional antidepressants, which also typically require four to six weeks to show meaningful effects.

3. Mild-to-moderate focus: Both this study and the three-arm trial focused on mild-to-moderate depression, which is precisely the population where an intervention with fewer side effects but somewhat lower efficacy might be most clinically appropriate. Patients with severe MDD, active suicidality, or psychotic features are not the target population for this kind of botanical intervention.

4. MSD Manuals acknowledgment: The fact that the MSD Manuals — a major professional medical reference — cites both of these studies [4] suggests that mainstream medical education is beginning to take Rhodiola's evidence base seriously, even if formal guideline recommendations are not yet in place.

This study, viewed alongside the three-arm trial, begins to establish a modest but real body of evidence for rhodiola rosea depression study outcomes in clinical populations.

What the 2022 Review Tells Us About Rhodiola Depression Evidence

In 2022, a systematic review published in PMC [1] synthesized the available clinical data on Rhodiola rosea for depression. This review is currently one of the top-ranking resources for anyone searching "rhodiola and depression clinical research" — and for good reason. It provides the most comprehensive quantitative synthesis of the available evidence.

Odds Ratios for Global Improvement

As noted above, the 2022 review calculated that by week 12:

• Patients taking Rhodiola had 1.4 times the odds of global improvement versus placebo
• Patients taking sertraline had 1.9 times the odds of global improvement versus placebo

These numbers come from pooled analysis of the clinical trial data and represent the clearest quantitative answer to the question: does Rhodiola work for depression? An odds ratio of 1.4 versus placebo is a clinically meaningful signal — modest, but real.

For context, many approved pharmaceutical treatments show odds ratios in the 1.3 to 1.5 range in rigorous placebo-controlled trials when accounting for publication bias. Rhodiola's signal, while below sertraline's in this dataset, is not dramatically out of step with what we expect from effective interventions in MDD.

What This Means for Rhodiola Depression Evidence

The rhodiola depression evidence picture emerging from the 2022 review is one of:

• Confirmed efficacy over placebo for mild-to-moderate MDD
• Inferior efficacy compared to sertraline at comparable doses and duration
• Superior tolerability compared to sertraline
• Consistent symptom-level improvements in specific domains (discussed in the next section)

This is not a ringing endorsement for replacing antidepressants with Rhodiola. But it is a meaningful enough signal that researchers, clinicians interested in integrative medicine, and patients seeking alternatives have legitimate scientific grounds for discussion.

Symptom-Level Benefits: Sleep, Mood, and Emotional Stability

One of the most clinically interesting findings in the rhodiola rosea clinical depression research is that benefits are not limited to overall depression scores. The 2022 review [1] identified statistically significant improvements in several specific symptom domains:

Insomnia

Sleep disturbance is both a symptom and a driver of depression. Disrupted sleep worsens mood, impairs cognitive function, reduces resilience to stress, and undermines the effectiveness of other treatments. The finding that Rhodiola produced a statistically significant reduction in insomnia alongside depression improvement is clinically relevant — it suggests the herb may be addressing one of the mechanistic drivers of depressive episodes, not just masking surface-level symptoms.

Emotional Instability

Emotional instability — characterized by rapid mood shifts, heightened reactivity, and difficulty regulating emotional responses — is a feature of many depressive presentations, particularly those with anxious or mixed features. The 2022 review found statistically significant improvements in this domain with Rhodiola, which aligns with the plant's proposed adaptogenic mechanism of action: buffering the nervous system's response to internal and external stressors.

This is one area where rhodiola mood regulation shows particular promise. The ability to reduce emotional volatility may be especially valuable for patients who feel "on edge" or overwhelmed, even when formal anxiety diagnoses are not present.

Somatization

Somatization refers to the expression of psychological distress through physical symptoms — unexplained pain, gastrointestinal complaints, fatigue, and similar physical manifestations. It is common in depression, particularly in cultures or individuals where psychological distress is more readily expressed through physical channels. Rhodiola's statistically significant benefit in this domain adds another dimension to its clinical profile beyond simple mood elevation.

The Combined Picture

Taken together, these symptom-level findings paint a picture of Rhodiola as a botanical that may support rhodiola and mood improvement through multiple pathways simultaneously — addressing sleep, emotional regulation, and physical manifestations of psychological distress alongside core depressive symptoms. This multi-domain action is consistent with its proposed adaptogenic mechanism and distinguishes it from single-target pharmacological interventions.

Dose and Duration: What the Research Suggests

One of the practical questions readers most often ask is: what dose of Rhodiola has been studied for depression, and how long does it take to work?

Dose Findings

The 2022 PMC review [1] identified a positive dose signal at 0.6 grams per day over 12 weeks. This is a meaningful data point for clinical practice, providing a specific, evidence-referenced dose rather than a vague range.

It is worth noting that:

• Rhodiola rosea extracts are typically standardized to their rosavin or salidroside content
• A dose of 0.6 g/day of a standardized extract is a moderate dose within the range typically used in clinical studies
• Higher doses were tested in the tolerability portion of the three-arm trial to establish maximum tolerable dose, which speaks to the importance of dose-finding work in this area

The standardization issue is important: not all Rhodiola products are equivalent. Extracts standardized to specific percentages of rosavins (typically 3%) and salidroside (typically 1%) are those most closely reflecting the formulations used in clinical research.

Duration Findings

Both the three-arm trial (12 weeks) and the smaller study (42 days, approximately 6 weeks) suggest that meaningful benefit requires sustained use over weeks, not days. This is consistent with:

• The mechanism of action — adaptogenic effects on the HPA axis and neurotransmitter systems likely require time to establish
• The timeline of antidepressant effects in general — SSRIs also typically require 4-8 weeks for full efficacy
• Patient expectations — individuals hoping for immediate effects may be disappointed, making expectation management important

The 12-week timeline in the primary trial is the most robust data point. Patients and clinicians considering Rhodiola for depression should plan for a trial of at least 6 to 12 weeks before evaluating response.

★★★★★ 4.8 · 1,247 reviews

See Why Athletes And Executives Take It Daily.

Adaptogen-based formula, third-party tested, made in the USA. Cancel subscription anytime.

Shop Cortisol Drops →

✓ 60-day guarantee ✓ Free shipping $40+ ✓ Ships in 24hrs

Emerging Research: What 2026 Studies Are Saying

The most recent evidence comes from a 2026 Frontiers review examining Rhodiola rosea alongside Ginkgo biloba and Ashwagandha as potential botanical approaches to mental health [6].

What the 2026 Review Concludes

The Frontiers review states that emerging clinical investigations in humans suggest Rhodiola may alleviate depressive manifestations, fatigue, and anxiety. It frames Rhodiola as a potential adjunctive strategy for depression management — not a replacement for evidence-based pharmacotherapy, but a meaningful addition to the therapeutic toolkit.

This framing is significant. "Adjunctive strategy" is careful, appropriately cautious language that acknowledges both the promise of the evidence and its current limitations. It positions Rhodiola within an integrative medicine framework rather than as an alternative to conventional care.

The Fatigue and Anxiety Connection

The 2026 review's emphasis on fatigue and anxiety alongside depression is clinically relevant. Depression and anxiety are highly comorbid — up to 60% of individuals with depression also meet criteria for an anxiety disorder. Fatigue is one of the most debilitating and treatment-resistant symptoms in depression. An intervention that addresses all three domains simultaneously — even modestly — has theoretical advantages over single-target treatments.

Rhodiola's proposed mechanisms (HPA axis modulation, monoamine support, adaptogenic stress buffering) are plausible explanations for this multi-domain benefit, though mechanism-level human studies remain limited.

The Research Gap

Notably, no dedicated rhodiola rosea depression study specific to depression was published in 2024 or 2025 in the available literature. The most recent depression-specific data synthesis remains the 2022 PMC review. This gap matters: the field would benefit significantly from:

• Larger randomized controlled trials (>200 participants)
• Studies examining Rhodiola as adjunctive therapy alongside SSRIs or SNRIs
• Longer follow-up periods (>12 weeks) to assess durability of benefit
• Studies in treatment-resistant depression
• Head-to-head comparisons with other herbal interventions (e.g., St. John's Wort)

Until these trials are completed, the evidence base — while genuine — remains relatively modest in scale.

Safety, Side Effects, and Drug Interactions

No discussion of rhodiola antidepressant research is complete without addressing safety. This is particularly important for individuals who may be considering Rhodiola alongside prescription antidepressants.

General Safety Profile

Rhodiola rosea has a favorable general safety profile based on the available clinical evidence. In the 12-week three-arm trial, the Rhodiola group showed fewer adverse effects than the sertraline group — a finding that is one of the more clinically compelling arguments for further research into this botanical.

Commonly reported side effects in clinical studies, when present, have included:

• Dizziness (particularly at higher doses)
• Dry mouth
• Mild agitation or restlessness (most common at doses higher than those typically used therapeutically)
• Occasional gastrointestinal upset

These side effects appear to be dose-dependent and generally mild in nature.

Drug Interactions — Critical Considerations

This is the area that requires the most caution. If you are considering Rhodiola alongside prescription medications, the following potential interactions are important to discuss with your healthcare provider:

Serotonergic medications: Because Rhodiola appears to influence serotonin pathways, combining it with SSRIs, SNRIs, MAOIs, or other serotonergic drugs carries a theoretical risk of serotonin syndrome — a potentially serious condition characterized by agitation, confusion, rapid heart rate, and hyperthermia. While no clinical cases have been definitively documented in the Rhodiola depression trials, the theoretical mechanism warrants caution. Do not combine Rhodiola with antidepressants without explicit medical supervision.

Anticoagulants: Rhodiola may have mild anticoagulant properties. Individuals taking warfarin, heparin, or other blood-thinning medications should discuss this with their prescriber.

Cytochrome P450 enzymes: Some evidence suggests Rhodiola may affect CYP450 enzyme activity, which could theoretically alter the metabolism of other medications. This interaction is not well-characterized in humans.

Diabetes medications: Rhodiola may have mild blood-sugar-lowering effects. Individuals on insulin or oral hypoglycemic agents should monitor carefully.

Stimulants: Rhodiola has mild stimulant-like properties at higher doses. Combining with caffeine or other stimulants may amplify these effects.

Who Should Be Cautious

• Pregnant or breastfeeding individuals (insufficient safety data)
• Children and adolescents (not studied in this population)
• Individuals with bipolar disorder (stimulant-like properties may theoretically trigger hypomanic episodes)
• Anyone with a history of mania
• Individuals on multiple medications (consult a pharmacist about interaction potential)

Current Guideline Status

It is important to be transparent: no major psychiatric or medical guideline currently recommends Rhodiola as a first-line or standard treatment for major depressive disorder. The evidence base, while promising, does not yet meet the threshold for formal guideline inclusion. Clinicians working in integrative medicine may discuss Rhodiola as a complementary option, but it should not replace evidence-based depression treatment, particularly for moderate-to-severe presentations.

Frequently Asked Questions

Does Rhodiola rosea actually help with depression?

Based on the available clinical evidence, yes — with important qualifications. A 12-week randomized controlled trial in 57 patients found that Rhodiola produced statistically significant improvement in depression scores compared to placebo. A separate 42-day study in 89 patients found similar benefits for mild-to-moderate depression. The 2022 PMC systematic review calculated that Rhodiola was associated with 1.4 times the odds of improvement versus placebo by week 12. This is a real but modest effect.

Is Rhodiola effective only for stress-related low mood, or for clinical MDD?

Both clinical studies discussed in this article enrolled patients with diagnosed mild-to-moderate major depressive disorder — not simply stress-related low mood. So the evidence specifically supports the idea that Rhodiola can benefit individuals with a clinical depression diagnosis, at least at the mild-to-moderate end of the severity spectrum.

How does Rhodiola compare to sertraline?

Sertraline was more effective than Rhodiola in the three-arm trial (1.9 vs 1.4 odds ratio for improvement versus placebo). However, Rhodiola caused significantly fewer adverse effects. The choice between them is a clinical trade-off that should be made in consultation with a healthcare provider.

What dose of Rhodiola has been studied for depression?

The 2022 review identified a positive signal at 0.6 grams per day over 12 weeks. Clinical studies have typically used standardized extracts containing 3% rosavins and 1% salidroside.

How quickly does Rhodiola work?

Clinical benefit was detected at 42 days in the smaller study and by 12 weeks in the larger trial. Most experts advise a minimum trial of 6 to 12 weeks before evaluating response.

Is Rhodiola safe to use with SSRIs or other antidepressants?

This is not recommended without explicit medical supervision. Theoretical serotonin syndrome risk, potential CYP450 interactions, and the complexity of combining any two neuroactive substances mean that a healthcare provider should be involved in any decision to combine Rhodiola with prescription antidepressants.

Does Rhodiola help with fatigue, insomnia, or anxiety alongside depression?

The 2022 review found statistically significant reductions in insomnia and emotional instability alongside overall depression improvement with Rhodiola. The 2026 Frontiers review specifically highlights Rhodiola's potential to alleviate fatigue and anxiety. These multi-domain benefits align with its proposed adaptogenic mechanism.

Are there high-quality randomized controlled trials?

There is one published randomized, double-blind, placebo-controlled trial with an active comparator arm (sertraline) in clinically diagnosed MDD. This meets a high methodological standard. However, the trial had only 57 participants — a relatively small sample size by pharmaceutical standards. The evidence base needs larger trials to achieve higher confidence levels.

Do clinical guidelines recommend Rhodiola for depression?

No. No major psychiatric or medical guideline currently recommends Rhodiola as a standard treatment for MDD. It is discussed in professional references like the MSD Manuals as an area of emerging research, but it has not achieved guideline status.

What side effects have been reported in Rhodiola depression studies?

The side effect profile was favorable in clinical trials — notably better than sertraline. When adverse effects occurred, they were typically mild and dose-dependent, including dizziness, dry mouth, mild agitation, and occasional gastrointestinal complaints.

★★★★★ 4.8 · 1,247 reviews

Ready To Try Adaptogen-Based Cortisol Support?

Third-party tested. 60-day guarantee. Free shipping over $40. Ships in 24 hours.

Shop Cortisol Drops →

✓ 60-day guarantee ✓ Free shipping $40+ ✓ Ships in 24hrs

Bottom Line: Is Rhodiola Ready for Clinical Use in Depression?

After reviewing the totality of available rhodiola and depression clinical research, the honest answer is: it depends on the clinical context.

What the Evidence Supports

• Rhodiola rosea produces statistically significant improvements in depression scores versus placebo in mild-to-moderate MDD (1.4 odds ratio for global improvement)
• It shows benefit across multiple symptom domains including insomnia, emotional instability, and somatization
• It has a superior tolerability profile compared to sertraline in the only head-to-head trial conducted
• The evidence is consistent across two independent studies and supported by a 2022 systematic review and a 2026 narrative review

What the Evidence Does Not Support

• That Rhodiola is as effective as sertraline or other first-line antidepressants
• That Rhodiola is appropriate as a replacement for prescription medication in moderate-to-severe depression
• That Rhodiola is safe to combine with antidepressants without medical supervision
• That formal guidelines recommend Rhodiola for MDD (they do not)

The Most Clinically Appropriate Use Cases

Based on the current evidence, Rhodiola is most appropriately considered for:

1. Adults with mild-to-moderate MDD who prefer to explore botanical options before or instead of prescription medication, under medical supervision
2. Patients who have experienced intolerable side effects from SSRIs and are seeking alternatives in consultation with their provider
3. Adjunctive support in an integrative treatment approach — not as a standalone replacement for evidence-based care
4. Individuals with comorbid fatigue and anxiety alongside depression, given Rhodiola's multi-domain symptom benefits

The Research Imperative

The field urgently needs larger, longer, and more diverse trials. A randomized controlled trial with 300+ participants, 6-month follow-up, adjunctive study arms, and diverse demographic representation would dramatically strengthen the evidence base. Until then, the honest scientific position is that rhodiola rosea depression study findings are promising but not definitive.

The rhodiola antidepressant effect is real. It is smaller than that of established medications. It comes with fewer side effects. And it shows intriguing multi-domain benefits across sleep, mood regulation, and physical symptoms of depression. For the right patient, in the right clinical context, with appropriate medical oversight, this combination of characteristics makes Rhodiola worth a serious, evidence-informed conversation.

That is exactly what good integrative medicine looks like: not abandoning the evidence hierarchy, but using it honestly to identify where botanical interventions genuinely add value — and where they do not.

This article synthesizes data from PMC clinical trial records [3], the 2022 PMC systematic review [1], the MSD Manuals professional reference [4], and a 2026 Frontiers review [6]. It is intended for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about depression treatment.

Sources:

1. PMC (2022). Systematic review on Rhodiola rosea for depression. https://pmc.ncbi.nlm.nih.gov/articles/PMC9228580/
2. MSD Manuals. Rhodiola professional reference. https://www.msdmanuals.com/professional/special-subjects/dietary-supplements/rhodiola
3. PMC (2014). Randomized trial of Rhodiola rosea for MDD. https://pmc.ncbi.nlm.nih.gov/articles/PMC4297663/
4. Frontiers (2026). Review of Rhodiola, Ginkgo biloba, and Ashwagandha in mental health.